SEC Company Response from HOOKIPA Pharma Inc. (HOOK) (CIK 0001760542) (HOOK) — Jul 19, 2022
HOOKIPA Pharma Inc. (HOOK) (CIK 0001760542)
Date: July 19, 2022 · CIK: 0001760542 · Accession: 0001104659-22-080841
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-266104
Letter
HOOKIPA Pharma Inc.
350 Fifth Avenue, 72nd Floor, Suite 7240
New York, New York 10118
July 19, 2022
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: HOOKIPA Pharma Inc.: Registration Statement on Form S-3 filed July 12, 2022 (File No. 333-266104)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), HOOKIPA Pharma Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to July 21, 2022, at 4:01 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
If you have any questions regarding this request, please contact Robert Puopolo of Goodwin Procter LLP at (617) 570-1393.
Sincerely,
HOOKIPA Pharma Inc.
Show Raw Text
CORRESP 1 filename1.htm HOOKIPA Pharma Inc. 350 Fifth Avenue, 72nd Floor, Suite 7240 New York, New York 10118 July 19, 2022 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: HOOKIPA Pharma Inc.: Registration Statement on Form S-3 filed July 12, 2022 (File No. 333-266104) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), HOOKIPA Pharma Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to July 21, 2022, at 4:01 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. If you have any questions regarding this request, please contact Robert Puopolo of Goodwin Procter LLP at (617) 570-1393. Sincerely, HOOKIPA Pharma Inc. /s/ Reinhard Kandera Reinhard Kandera Chief Financial Officer cc: Joern Aldag, HOOKIPA Pharma Inc. Daniel Courtney, Esq. HOOKIPA Pharma Inc. Robert Puopolo, Esq., Goodwin Procter LLP Seo Salimi, Esq., Goodwin Procter LLP